You can buy Semedx at the lowest price in the online pharmacy Nextgen.ooo . Selumetinib is a MEK 1/2 inhibitor used in pediatric patients for the treatment of neurofibromatosis type 1 (NF1) accompanied by symptomatic unresectable plexiform neurofibromas (PN).
 
The Raf-MEK-ERK signaling pathway is known to be activated in several types of malignancies; thus, mitogen-activated protein kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic hyperactivity of this pathway. The results of clinical trials of previously developed MEK inhibitors have been disappointing. However, selumetinib has demonstrated impressive efficacy and tolerability in phase I studies, leading to its further exploration for the treatment of various tumor types in phase II studies.
 
Currently, a new MEK 1/2 inhibitor, selumetinib, is approved exclusively for the treatment of neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare, with an estimated incidence of 1/3,000 people. It is a genetic, autosomal dominant disorder caused by a mutation in the NF1 gene that can lead to various complications, including the development of multiple tumors of the nervous system. Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered relatively rare compared to other NF-1 variants. Fortunately, selumetinib has been shown to be effective in reducing associated tumors in patients with NF-1 and is associated with other positive clinical outcomes. Selumetinib was approved by the FDA on April 10, 2020.